<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231114212152&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231114212152&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 15 Nov 2023 02:21:54 +0000</lastbuilddate>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Response by Sipilä and Kivimäki to Letter Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1509-1510. doi: 10.1161/CIRCULATIONAHA.123.066622. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37963202</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066622>10.1161/CIRCULATIONAHA.123.066622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963202</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Pyry N Sipilä</dc:creator>
<dc:creator>Mika Kivimäki</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Sipilä and Kivimäki to Letter Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</dc:title>
<dc:identifier>pmid:37963202</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066622</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1505-1506. doi: 10.1161/CIRCULATIONAHA.123.067091. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37963201</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067091>10.1161/CIRCULATIONAHA.123.067091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963201</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:37963201</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067091</dc:identifier>
</item>
<item>
<title>Hot topics in valvular heart disease: tricuspid regurgitation, bicuspid aortic valve, artificial intelligence for aortic stenosis, and aortic aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963104/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 14;44(43):4493-4496. doi: 10.1093/eurheartj/ehad743.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963104/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37963104</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad743>10.1093/eurheartj/ehad743</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963104</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in valvular heart disease: tricuspid regurgitation, bicuspid aortic valve, artificial intelligence for aortic stenosis, and aortic aneurysm</dc:title>
<dc:identifier>pmid:37963104</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad743</dc:identifier>
</item>
<item>
<title>JAMA Cardiology Peer Reviewers in 2022</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37962873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 May 1;8(5):e230142. doi: 10.1001/jamacardio.2023.0142. Epub 2023 May 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37962873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37962873</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.0142>10.1001/jamacardio.2023.0142</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37962873</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology Peer Reviewers in 2022</dc:title>
<dc:identifier>pmid:37962873</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.0142</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37962872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 May 1;8(5):411. doi: 10.1001/jamacardio.2022.3436.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37962872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37962872</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2022.3436>10.1001/jamacardio.2022.3436</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37962872</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:37962872</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2022.3436</dc:identifier>
</item>
<item>
<title>Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.065600. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men in the EXPLORER-HCM study (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prespecified post hoc analysis of sex from the blinded, randomized EXPLORER-HCM trial of mavacamten versus placebo in symptomatic patients with obstructive HCM was performed. Baseline characteristics were compared with <i>t</i> tests for continuous variables (expressed as mean values) and χ<sup>2</sup> tests for categorical variables. Prespecified primary, secondary, and exploratory end points and echocardiographic measurements from baseline to end of treatment (week 30) were analyzed with ANCOVA for continuous end points and a generalized linear model with binomial distribution for binary end points, with adjustment for the baseline of each outcome, New York Heart Association class, β-blocker use, and ergometer type.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, women (n=102) were older (62 years versus 56 years; <i>P</i>&lt;0.0001), had lower peak oxygen consumption (16.7 mL·kg<sup>-1</sup>·min<sup>-1</sup> versus 21.3 mL·kg<sup>-1</sup>·min<sup>-1</sup>; <i>P</i>&lt;0.0001), were more likely to be assigned New York Heart Association class III (42% versus 17%; <i>P</i>&lt;0.0001), had worse health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 64 versus 75; <i>P</i>&lt;0.0001), and had higher baseline plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (1704 ng/L versus 990 ng/L; <i>P</i>=0.004) than men (n=149). After 30 weeks of mavacamten treatment, similar improvements were observed in women and men in the primary composite end point (percentage difference on mavacamten versus placebo, 22% versus 19%, respectively; <i>P</i>=0.759) and in the secondary end points of change in postexercise left ventricular outflow tract gradient (-42.4 mm Hg versus -33.6 mm Hg; <i>P</i>=0.348), change in peak oxygen consumption (1.2 mL·kg<sup>-1</sup>·min<sup>-1</sup> versus 1.6 mL·kg<sup>-1</sup>·min<sup>-1</sup>; <i>P</i>=0.633), and percentage achieving ≥1 New York Heart Association class improvement (41% versus 28%; <i>P</i>=0.254). However, women had greater improvement in health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 14.8 versus 6.1; <i>P</i>=0.026) and in the exploratory end point of NT-proBNP levels (-1322 ng/L versus -649 ng/L; <i>P</i>=0.0008).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03470545.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37961906</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065600>10.1161/CIRCULATIONAHA.123.065600</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961906</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sharon Cresci</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Sheila M Hegde</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Ester Kim Nilles</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</dc:title>
<dc:identifier>pmid:37961906</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065600</dc:identifier>
</item>
<item>
<title>Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. Therefore, activation of ERR could be a potential therapeutic intervention for HF. However, in vivo studies demonstrating the potential usefulness of ERR agonist for HF treatment are lacking, because compounds with pharmacokinetics appropriate for in vivo use have not been available.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a structure-based design approach, we designed and synthesized 2 structurally distinct pan-ERR agonists, SLU-PP-332 and SLU-PP-915. We investigated the effect of ERR agonist on cardiac function in a pressure overload-induced HF model in vivo. We conducted comprehensive functional, multi-omics (RNA sequencing and metabolomics studies), and genetic dependency studies both in vivo and in vitro to dissect the molecular mechanism, ERR isoform dependency, and target specificity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced HF without affecting cardiac hypertrophy. A broad spectrum of metabolic genes was transcriptionally activated by ERR agonists, particularly genes involved in fatty acid metabolism and mitochondrial function. Metabolomics analysis showed substantial normalization of metabolic profiles in fatty acid/lipid and tricarboxylic acid/oxidative phosphorylation metabolites in the mouse heart with 6-week pressure overload. ERR agonists increase mitochondria oxidative capacity and fatty acid use in vitro and in vivo. Using both in vitro and in vivo genetic dependency experiments, we show that ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection and definitively demonstrated target specificity. ERR agonism also led to downregulation of cell cycle and development pathways, which was partially mediated by E2F1 in cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37961903</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066542>10.1161/CIRCULATIONAHA.123.066542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961903</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Weiyi Xu</dc:creator>
<dc:creator>Cyrielle Billon</dc:creator>
<dc:creator>Hui Li</dc:creator>
<dc:creator>Andrea Wilderman</dc:creator>
<dc:creator>Lei Qi</dc:creator>
<dc:creator>Andrea Graves</dc:creator>
<dc:creator>Jernie Rae Dela Cruz Rideb</dc:creator>
<dc:creator>Yuanbiao Zhao</dc:creator>
<dc:creator>Matthew Hayes</dc:creator>
<dc:creator>Keyang Yu</dc:creator>
<dc:creator>McKenna Losby</dc:creator>
<dc:creator>Carissa S Hampton</dc:creator>
<dc:creator>Christiana M Adeyemi</dc:creator>
<dc:creator>Seok Jae Hong</dc:creator>
<dc:creator>Eleni Nasiotis</dc:creator>
<dc:creator>Chen Fu</dc:creator>
<dc:creator>Tae Gyu Oh</dc:creator>
<dc:creator>Weiwei Fan</dc:creator>
<dc:creator>Michael Downes</dc:creator>
<dc:creator>Ryan D Welch</dc:creator>
<dc:creator>Ronald M Evans</dc:creator>
<dc:creator>Aleksandar Milosavljevic</dc:creator>
<dc:creator>John K Walker</dc:creator>
<dc:creator>Brian C Jensen</dc:creator>
<dc:creator>Liming Pei</dc:creator>
<dc:creator>Thomas Burris</dc:creator>
<dc:creator>Lilei Zhang</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function</dc:title>
<dc:identifier>pmid:37961903</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066542</dc:identifier>
</item>
<item>
<title>Nitric Oxide Modulates Ca&lt;sup>;2+&lt;/sup>; Leak and Arrhythmias via S-Nitrosylation of CaMKII</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We conclude that prior S-nitrosylation of CaMKIIδ at cysteine-273 can limit subsequent β-adrenergic receptor-induced arrhythmias, but that S-nitrosylation at cysteine-290 might worsen or sustain β-adrenergic receptor-induced arrhythmias. This has important implications for the administration of NO donors in the clinical setting.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 14. doi: 10.1161/CIRCRESAHA.123.323571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Nitric oxide (NO) has been identified as a signaling molecule generated during β-adrenergic receptor stimulation in the heart. Furthermore, a role for NO in triggering spontaneous Ca<sup>2+</sup> release via <i>S</i>-nitrosylation of CaMKIIδ (Ca<sup>2+</sup>/calmodulin kinase II delta) is emerging. NO donors are routinely used clinically for their cardioprotective effects on the heart, but it is unknown how NO donors modulate the proarrhythmic CaMKII to alter cardiac arrhythmia incidence. We test the role of <i>S</i>-nitrosylation of CaMKIIδ at the Cysteine-273 inhibitory site and cysteine-290 activating site in cardiac Ca<sup>2+</sup> handling and arrhythmogenesis before and during β-adrenergic receptor stimulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured Ca<sup>2+</sup>-handling in isolated cardiomyocytes from C57BL/6J wild-type (WT) mice and mice lacking CaMKIIδ expression (CaMKIIδ-KO) or with deletion of the <i>S</i>-nitrosylation site on CaMKIIδ at cysteine-273 or cysteine-290 (CaMKIIδ-C273S and -C290A knock-in mice). Cardiomyocytes were exposed to NO donors, <i>S</i>-nitrosoglutathione (GSNO; 150 μM), sodium nitroprusside (200 μM), and β-adrenergic agonist isoproterenol (100 nmol/L).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both WT and CaMKIIδ-KO cardiomyocytes responded to isoproterenol with a full inotropic and lusitropic Ca<sup>2+</sup> transient response as well as increased Ca<sup>2+</sup> spark frequency. However, the increase in Ca<sup>2+</sup> spark frequency was significantly attenuated in CaMKIIδ-KO cardiomyocytes. The protection from isoproterenol-induced Ca<sup>2+</sup> sparks and waves was mimicked by GSNO pretreatment in WT cardiomyocytes but lost in CaMKIIδ-C273S cardiomyocytes. When GSNO was applied after isoproterenol, this protection was not observed in WT or CaMKIIδ-C273S but was apparent in CaMKIIδ-C290A. In Langendorff-perfused isolated hearts, GSNO pretreatment limited isoproterenol-induced arrhythmias in WT but not CaMKIIδ-C273S hearts, while GSNO exposure after isoproterenol sustained or exacerbated arrhythmic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We conclude that prior <i>S</i>-nitrosylation of CaMKIIδ at cysteine-273 can limit subsequent β-adrenergic receptor-induced arrhythmias, but that <i>S</i>-nitrosylation at cysteine-290 might worsen or sustain β-adrenergic receptor-induced arrhythmias. This has important implications for the administration of NO donors in the clinical setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37961889</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323571>10.1161/CIRCRESAHA.123.323571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961889</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Amelia S Power</dc:creator>
<dc:creator>Esther U Asamudo</dc:creator>
<dc:creator>Luke P I Worthington</dc:creator>
<dc:creator>Chidera C Alim</dc:creator>
<dc:creator>Raquel E Parackal</dc:creator>
<dc:creator>Rachel S Wallace</dc:creator>
<dc:creator>Obialunanma V Ebenebe</dc:creator>
<dc:creator>Joan Heller Brown</dc:creator>
<dc:creator>Mark J Kohr</dc:creator>
<dc:creator>Donald M Bers</dc:creator>
<dc:creator>Jeffrey R Erickson</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Nitric Oxide Modulates Ca&lt;sup>;2+&lt;/sup>; Leak and Arrhythmias via S-Nitrosylation of CaMKII</dc:title>
<dc:identifier>pmid:37961889</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323571</dc:identifier>
</item>
<item>
<title>Cooperative Response to Endocardial Notch Reveals Interaction With Hippo Pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Sequential Notch-dependent transcriptional regulation in the embryonic endocardium involves multiple factors. Notch activates certain noncoding elements through these factors and simultaneously suppresses elements that could hinder cardiac valve development and homeostasis. Biorxviv: https://www.biorxiv.org/content/10.1101/2023.03.23.533882v1.full.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 14. doi: 10.1161/CIRCRESAHA.123.323474. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The endocardium is a crucial signaling center for cardiac valve development and maturation. Genetic analysis has identified several human endocardial genes whose inactivation leads to bicuspid aortic valve formation and calcific aortic valve disease, but knowledge is very limited about the role played in valve development and disease by noncoding endocardial regulatory regions and upstream factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We manipulated Notch signaling in mouse embryonic endocardial cells by short-term and long-term coculture with OP9 stromal cells expressing Notch ligands and inhibition of Notch activity. We examined the transcriptional profile and chromatin accessibility landscape for each condition, integrated transcriptomic, transcription factor occupancy, chromatin accessibility, and proteomic datasets. We generated in vitro and in vivo models with CRISPR-Cas9-edited deletions of various noncoding regulatory elements and validated their regulatory potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified primary and secondary transcriptional responses to Notch ligands in the mouse embryonic endocardium, and a NOTCH-dependent transcriptional signature in valve development and disease. By defining the changes in the chromatin accessibility landscape and integrating with the landscape in developing mouse endocardium and adult human valves, we identify potential noncoding regulatory elements, validated selected candidates, propose interacting cofactors, and define the timeframe of their regulatory activity. Additionally, we found cooperative transcriptional repression with Hippo pathway by inhibiting nuclear Yap (Yes-associated protein) activity in the endocardium during cardiac valve development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sequential Notch-dependent transcriptional regulation in the embryonic endocardium involves multiple factors. Notch activates certain noncoding elements through these factors and simultaneously suppresses elements that could hinder cardiac valve development and homeostasis. Biorxviv: https://www.biorxiv.org/content/10.1101/2023.03.23.533882v1.full.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37961886</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323474>10.1161/CIRCRESAHA.123.323474</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961886</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Luis Luna-Zurita</dc:creator>
<dc:creator>Brenda Giselle Flores-Garza</dc:creator>
<dc:creator>Dimitrios Grivas</dc:creator>
<dc:creator>Marcos Siguero-Álvarez</dc:creator>
<dc:creator>José Luis de la Pompa</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cooperative Response to Endocardial Notch Reveals Interaction With Hippo Pathway</dc:title>
<dc:identifier>pmid:37961886</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323474</dc:identifier>
</item>
<item>
<title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 13. doi: 10.1038/s41569-023-00959-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37957335</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00959-y>10.1038/s41569-023-00959-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37957335</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</dc:title>
<dc:identifier>pmid:37957335</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00959-y</dc:identifier>
</item>
<item>
<title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 8:S0735-1097(23)07988-3. doi: 10.1016/j.jacc.2023.11.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the ISCHEMIA trial, the risk of ischemic events was similar in patients with stable coronary artery disease treated with an invasive (INV) strategy of angiography and percutaneous (PCI) or surgical (CABG) coronary revascularization and a conservative (CON) strategy of initial medical therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To analyze separately the outcomes of INV patients treated with PCI or CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients without preceding primary outcome events were categorized as INV-PCI or INV-CABG from the time of revascularization. The ISCHEMIA primary outcome (composite of cardiovascular death, protocol-defined myocardial infarction (MI) or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest) was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among INV-CABG patients, primary outcome events occurred in 84/512 (16.4%) at median follow-up of 2.85 years; 48 events (57.1%) occurred within 30 days after CABG, including 40 procedural MIs; among INV-PCI patients, primary outcome events occurred in 147/1500 (9.8%) at median follow-up of 2.94 years; 31 of which (21.1%) within 30 days after PCI, including 23 procedural MIs. In comparison, 352/2591 (13.6%) CON patients had primary outcome events at median follow-up 3.2 years, 22 of which (6.3%) within 30 days of randomization. The adjusted primary outcome risks (HR [95%CI]) were higher after both CABG and PCI within 30 days (16.25 (11.44-23.07) and 2.99 (1.97-4.53)) and lower thereafter (0.63 (0.44-0.89) and 0.66(0.53-0.82)).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956961</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.002>10.1016/j.jacc.2023.11.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956961</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Eric R Bates</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Giuseppe Biondi-Zoccai</dc:creator>
<dc:creator>Tulio Caldonazo</dc:creator>
<dc:creator>Michael Farkouh</dc:creator>
<dc:creator>Mohamed Rahouma</dc:creator>
<dc:creator>John Puskas</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Mario Fl Gaudino</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:37956961</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.002</dc:identifier>
</item>
<item>
<title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 13:ehad770. doi: 10.1093/eurheartj/ehad770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: ECG abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD) but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study population was drawn from two prospective community-based SCD studies in Oregon, USA (2002-, discovery cohort) and California, USA (2015-, validation cohort). For this present sub-study, 231 discovery cases (2015-2017) and 203 validation cases (2015-2021) with ≥2 archived pre-SCD ECGs were ascertained, and were matched to 234 discovery and 203 validation controls based on age, sex, and duration between the ECGs. Dynamic ECG remodeling was measured as progression of a previously validated cumulative 6-variable ECG electrical risk score (ERS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Oregon SCD cases displayed greater ERS increase over time vs. controls [+1.06 (95% CI +0.89 to +1.24) vs. -0.05 (-0.21 to +0.11); p &lt; 0.001]. These findings were successfully replicated in California [+0.87 (+0.7 to +1.04) vs. -0.11 (-0.27 to 0.05); p &lt; 0.001]. In multivariable models, abnormal dynamic ECG remodeling improved SCD prediction over baseline ECG, demographics, and clinical SCD risk factors in both Oregon [AUC 0.770 (95% CI 0.727-0.812) increased to AUC 0.869 (95% CI 0.837-0.902)] and California cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad770>10.1093/eurheartj/ehad770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956651</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>H N Pham</dc:creator>
<dc:creator>L Holmstrom</dc:creator>
<dc:creator>H Chugh</dc:creator>
<dc:creator>A Uy-Evanado</dc:creator>
<dc:creator>K Nakamura</dc:creator>
<dc:creator>Z Zhang</dc:creator>
<dc:creator>A Salvucci</dc:creator>
<dc:creator>J Jui</dc:creator>
<dc:creator>K Reinier</dc:creator>
<dc:creator>S S Chugh</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</dc:title>
<dc:identifier>pmid:37956651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad770</dc:identifier>
</item>
<item>
<title>Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 12:ehad771. doi: 10.1093/eurheartj/ehad771. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with long atrial high-rate episodes (AHRE) ≥ 24 hours and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared to no anticoagulation in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This secondary prespecified analysis of NOAH-AFNET 6 examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared to placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and ECG-diagnosed atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AHRE ≥24 hours were present at baseline in 259/2389 patients enrolled in NOAH-AFNET 6 (11%, 78 ± 7 years old, 28% women, CHA2DS2-VASc score 4). Clinical characteristics were not different from patients with shorter AHRE. During a median follow-up of 1.8 years, the primary outcome occurred in 9/132 patients with AHRE ≥24 hours (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). AHRE duration did not interact with the efficacy (p-interaction = 0.65) or safety (p-interaction = 0.98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE ≥24 hours developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; p &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956458</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad771>10.1093/eurheartj/ehad771</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956458</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>Tobias Toennis</dc:creator>
<dc:creator>Emanuele Bertaglia</dc:creator>
<dc:creator>Carina Blomström-Lundqvist</dc:creator>
<dc:creator>Axel Brandes</dc:creator>
<dc:creator>Nuno Cabanelas</dc:creator>
<dc:creator>Melanie Calvert</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Gregory Chlouverakis</dc:creator>
<dc:creator>Gheorghe-Andrei Dan</dc:creator>
<dc:creator>Wolfgang Dichtl</dc:creator>
<dc:creator>Hans Christoph Diener</dc:creator>
<dc:creator>Alexander Fierenz</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Joris R de Groot</dc:creator>
<dc:creator>Astrid N L Hermans</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Andrzej Lubinski</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Lluís Mont</dc:creator>
<dc:creator>Ann-Kathrin Ozga</dc:creator>
<dc:creator>Kim Rajappan</dc:creator>
<dc:creator>Andrea Sarkozy</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Susanne Sehner</dc:creator>
<dc:creator>Emmanuel Simantirakis</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Vasil Velchev</dc:creator>
<dc:creator>Dan Wichterle</dc:creator>
<dc:creator>Antonia Zapf</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours</dc:title>
<dc:identifier>pmid:37956458</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad771</dc:identifier>
</item>
<item>
<title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):e185. doi: 10.1161/CIR.0000000000001190. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001190>10.1161/CIR.0000000000001190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956227</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37956227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001190</dc:identifier>
</item>
<item>
<title>Risk Stratification in Brugada Syndrome: How Low Can We Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1556-1558. doi: 10.1161/CIRCULATIONAHA.123.066697. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956226</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066697>10.1161/CIRCULATIONAHA.123.066697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956226</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Johan Saenen</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk Stratification in Brugada Syndrome: How Low Can We Go?</dc:title>
<dc:identifier>pmid:37956226</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066697</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1602-1603. doi: 10.1161/CIRCULATIONAHA.123.066427. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956225</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066427>10.1161/CIRCULATIONAHA.123.066427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956225</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Man-Ru Zhang</dc:creator>
<dc:creator>Dan-Dan Guo</dc:creator>
<dc:creator>Jing Zhao</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</dc:title>
<dc:identifier>pmid:37956225</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066427</dc:identifier>
</item>
<item>
<title>Response by Cho and Yoon to Letter Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1604-1605. doi: 10.1161/CIRCULATIONAHA.123.066624. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956224</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066624>10.1161/CIRCULATIONAHA.123.066624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956224</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kyu-Won Cho</dc:creator>
<dc:creator>Young-Sup Yoon</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Cho and Yoon to Letter Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</dc:title>
<dc:identifier>pmid:37956224</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066624</dc:identifier>
</item>
<item>
<title>Studying Long QT Syndrome Caused by &lt;em>;NAA10&lt;/em>; Genetic Variants Using Patient-Derived Induced Pluripotent Stem Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1598-1601. doi: 10.1161/CIRCULATIONAHA.122.061864. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956223</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061864>10.1161/CIRCULATIONAHA.122.061864</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956223</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nadjet Belbachir</dc:creator>
<dc:creator>Yiyang Wu</dc:creator>
<dc:creator>Mengcheng Shen</dc:creator>
<dc:creator>Sophia L Zhang</dc:creator>
<dc:creator>Joe Z Zhang</dc:creator>
<dc:creator>Chun Liu</dc:creator>
<dc:creator>Bjorn C Knollmann</dc:creator>
<dc:creator>Gholson J Lyon</dc:creator>
<dc:creator>Ning Ma</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Studying Long QT Syndrome Caused by &lt;em>;NAA10&lt;/em>; Genetic Variants Using Patient-Derived Induced Pluripotent Stem Cells</dc:title>
<dc:identifier>pmid:37956223</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061864</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1593-1597. doi: 10.1161/CIRCULATIONAHA.123.067572. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956222</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067572>10.1161/CIRCULATIONAHA.123.067572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956222</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:37956222</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067572</dc:identifier>
</item>
<item>
<title>A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37956127</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067528>10.1161/CIRCULATIONAHA.123.067528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956127</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kazuya Hosokawa</dc:creator>
<dc:creator>Hiroko Watanabe</dc:creator>
<dc:creator>Yu Taniguchi</dc:creator>
<dc:creator>Nobutaka Ikeda</dc:creator>
<dc:creator>Takumi Inami</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:creator>Toyoaki Murohara</dc:creator>
<dc:creator>Masaru Hatano</dc:creator>
<dc:creator>Yuichi Tamura</dc:creator>
<dc:creator>Jun Yamashita</dc:creator>
<dc:creator>Koichiro Tatsumi</dc:creator>
<dc:creator>Ichizo Tsujino</dc:creator>
<dc:creator>Yuko Kobayakawa</dc:creator>
<dc:creator>Shiro Adachi</dc:creator>
<dc:creator>Nobuhiro Yaoita</dc:creator>
<dc:creator>Shun Minatsuki</dc:creator>
<dc:creator>Koji Todaka</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Hiroyuki Tsutsui</dc:creator>
<dc:creator>Kohtaro Abe</dc:creator>
<dc:creator>KABUKI Investigators</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial</dc:title>
<dc:identifier>pmid:37956127</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067528</dc:identifier>
</item>
<item>
<title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114212152&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4776. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Patients were categorized by HF type and further divided by loop diuretic strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P &lt; .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P &lt; .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114212152&v=2.17.9.post6+86293ac">37955908</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955908</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Selim R Krim</dc:creator>
<dc:creator>Senthil Anand</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Anqi Chen</dc:creator>
<dc:creator>Daniel Wojdyla</dc:creator>
<dc:creator>Juan Vilaro</dc:creator>
<dc:creator>Herbert Haught</dc:creator>
<dc:creator>John M Herre</dc:creator>
<dc:creator>Eric L Eisenstein</dc:creator>
<dc:creator>Kevin J Anstrom</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37955908</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4776</dc:identifier>
</item>





























</channel>
</rss>